VolitionRx Limited to Present at Jefferies Global Healthcare Conference
VolitionRx (NYSE AMERICAN: VNRX), a multi-national epigenetics firm, announced that its President and Group CEO, Cameron Reynolds, will present at the Jefferies Global Healthcare Conference in New York City on June 5, 2024, at 3:30 pm ET. The company aims to showcase its portfolio of patented epigenetic technologies for the early detection and monitoring of diseases such as sepsis and cancer. Investors are invited to schedule one-on-one meetings with the executive team by contacting investorrelations@volition.com.
- VolitionRx's participation in the Jefferies Global Healthcare Conference, a prestigious industry event, enhances visibility.
- Scheduled presentation by CEO Cameron Reynolds highlights leadership engagement and commitment.
- Opportunity to showcase patented epigenetic technologies could attract new investors and partnerships.
- No new financial data or clinical results were disclosed in the announcement, potentially leaving investors wanting more concrete updates.
- Focus on presentation without any mention of upcoming products or sales projections may be seen as lacking in forward-looking business metrics.
Presentation Details:
Date: Wednesday, June 5, 2024
Time: 3.30 pm ET (Track 3)
Cameron Reynolds, President and Group CEO of Volition, said: "We are dedicated to improving outcomes for people and animals with life-altering diseases such as sepsis and cancer through earlier detection, disease and treatment monitoring. We look forward to presenting our extensive portfolio of patented epigenetic technologies at the Jefferies Global Healthcare Conference."
Investors can schedule a one-to-one meeting with Volition's Executive Team by emailing investorrelations@volition.com.
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients, but also improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition, mediarelations@volition.com +44 (0)7557 774620
View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-to-present-at-jefferies-global-healthcare-conference-302157932.html
SOURCE VolitionRx Limited
FAQ
When and where will VolitionRx present at the Jefferies Global Healthcare Conference?
What will VolitionRx showcase at the Jefferies Global Healthcare Conference?
Who will represent VolitionRx at the Jefferies Global Healthcare Conference?
How can investors schedule a meeting with VolitionRx's executive team at the Jefferies Global Healthcare Conference?
